Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $29,532 | 8 | 91.5% |
| Consulting Fee | $2,040 | 1 | 6.3% |
| Food and Beverage | $624.57 | 8 | 1.9% |
| Education | $89.00 | 1 | 0.3% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Pharmacyclics LLC, An AbbVie Company | $25,708 | 4 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $3,841 | 5 | $0 (2024) |
| Medexus Pharma, Inc. | $2,040 | 1 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $511.74 | 5 | $0 (2024) |
| Astellas Pharma US Inc | $89.00 | 1 | $0 (2017) |
| Janssen Scientific Affairs, LLC | $60.02 | 1 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $35.60 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,863 | 3 | Medexus Pharma, Inc. ($2,040) |
| 2023 | $763.42 | 5 | Novartis Pharmaceuticals Corporation ($431.05) |
| 2022 | $236.02 | 2 | NOVARTIS PHARMACEUTICALS CORPORATION ($176.00) |
| 2020 | $2,500 | 1 | Novartis Pharmaceuticals Corporation ($2,500) |
| 2019 | $25,695 | 4 | Pharmacyclics LLC, An AbbVie Company ($25,587) |
| 2018 | $139.05 | 2 | Pharmacyclics LLC, An AbbVie Company ($121.84) |
| 2017 | $89.00 | 1 | Astellas Pharma US Inc ($89.00) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $106.12 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 06/13/2024 | Medexus Pharma, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,040.00 | General |
| 02/06/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | — | Cash or cash equivalent | $716.83 | Research |
| Study: CCTL019B2401 • Category: Oncology | ||||||
| 09/06/2023 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $41.22 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 06/27/2023 | JAZZ PHARMACEUTICALS INC. | DEFITELIO (Drug) | Food and Beverage | In-kind items and services | $114.58 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 05/09/2023 | JAZZ PHARMACEUTICALS INC. | DEFITELIO (Drug) | Food and Beverage | In-kind items and services | $140.97 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 02/17/2023 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | — | Cash or cash equivalent | $431.05 | Research |
| Study: CTL019B2401 • Category: Oncology | ||||||
| 02/15/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $35.60 | General |
| Category: Rare Disease | ||||||
| 09/30/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | KYMRIAH (Biological) | — | In-kind items and services | $176.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 04/24/2022 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $60.02 | General |
| Category: Oncology | ||||||
| 12/18/2020 | Novartis Pharmaceuticals Corporation | KYMRIAH (Biological) | — | In-kind items and services | $2,500.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: ONCOLOGY | ||||||
| 05/06/2019 | Pharmacyclics LLC, An AbbVie Company | Ibrutinib (Drug) | — | Cash or cash equivalent | $6,400.00 | Research |
| Study: PCYC-1146-IM • Category: Oncology | ||||||
| 04/30/2019 | JAZZ PHARMACEUTICALS INC. | DEFITELIO (Drug) | Food and Beverage | In-kind items and services | $108.85 | General |
| Category: HEMATOLOGY | ||||||
| 04/05/2019 | Pharmacyclics LLC, An AbbVie Company | Ibrutinib (Drug) | — | Cash or cash equivalent | $19,066.58 | Research |
| Study: PCYC-1146-IM • Category: Oncology | ||||||
| 02/22/2019 | Pharmacyclics LLC, An AbbVie Company | Ibrutinib (Drug) | — | Cash or cash equivalent | $120.02 | Research |
| Study: PCYC-1140-IM • Category: Oncology | ||||||
| 11/06/2018 | Novartis Pharmaceuticals Corporation | KYMRIAH (Biological) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2018 | Pharmacyclics LLC, An AbbVie Company | Ibrutinib (Drug) | — | Cash or cash equivalent | $121.84 | Research |
| Study: PCYC-1140-IM • Category: Oncology | ||||||
| 07/06/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $89.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PCYC-1146-IM | Pharmacyclics LLC, An AbbVie Company | $25,467 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $2,500 | 1 |
| CCTL019B2401 | Novartis Pharmaceuticals Corporation | $716.83 | 1 |
| CTL019B2401 | Novartis Pharmaceuticals Corporation | $431.05 | 1 |
| PCYC-1140-IM | Pharmacyclics LLC, An AbbVie Company | $241.86 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $176.00 | 1 |
About Dr. Amy Keating, MD
Dr. Amy Keating, MD is a Pediatric Hematology-Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447335195.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amy Keating, MD has received a total of $32,286 in payments from pharmaceutical and medical device companies, with $2,863 received in 2024. These payments were reported across 18 transactions from 7 companies. The most common payment nature is "" ($29,532).
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Boston, MA
- Active Since 10/25/2006
- Last Updated 08/02/2023
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1447335195
Products in Payments
- Ibrutinib (Drug) $25,708
- KYMRIAH (Biological) $2,693
- KYMRIAH (Drug) $1,148
- DEFITELIO (Drug) $364.40
- RYLAZE (Drug) $147.34
- IMBRUVICA (Drug) $60.02
- ULTOMIRIS (Biological) $35.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Boston
Mr. Alan Dandrea, Md, MD
Pediatric Hematology-Oncology — Payments: $826,972
Dr. Leslie Kean, Md/Phd, MD/PHD
Pediatric Hematology-Oncology — Payments: $326,453
Todd Golub, M.d, M.D
Pediatric Hematology-Oncology — Payments: $247,953
Dr. Stacy Croteau, Md, MD
Pediatric Hematology-Oncology — Payments: $219,942
Matthew Heeney, Md, MD
Pediatric Hematology-Oncology — Payments: $201,707
Christine Duncan, M.d, M.D
Pediatric Hematology-Oncology — Payments: $74,023